A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

This is an interventional treatment trial for Primary Refractory Neuroblastoma focused on measuring Neuroblastoma, 3F8, Primary refractory Read More

Inclusion Criteria:

• Have a diagnosis of stage 4 neuroblastoma diagnosed in accordance with the International Neuroblastoma Staging System: either (a) histologic confirmation which may involve immunohistochemical, ultrastructural, and/or cytogenetic studies, or (b) elevated urinary catecholamines plus tumor cells/clumps in the bone marrow.
• Have evaluable disease or biopsy-proven stable disease in BM by histology or MIBG scan with MIBG-positive disease confined to the bone or bone marrow, plus urine catecholamine results, documented >3 weeks after conventional chemotherapy or >6 weeks after stem-cell transplantation. CT, MRI, or bone scan (if necessary) can be done at 2-3 weeks after conventional chemotherapy confirming that the chemotherapy, radiotherapy, and ABMT are not realistic curative options.
• Be between 18 months to 13 years old at diagnosis.
• Have recovered to grade 2 or better toxicities since their prior therapy.
• Must, if female of childbearing potential, be willing to use two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at screening and monthly thereafter through the first four cycles of treatment.
• Have a performance score of at least 60 from Lansky Play Performance Scale if aged up to 16 years or at least 60 from Karnofsky Scale if aged more than 16 years.
• Have voluntarily agreed to participate.

Exclusion Criteria:

• Have measurable disease ≥ 1 cm assessed by CT or MRI.
• Have progressive disease (any new lesion; increase of any measurable lesion by >25%; or previous negative marrow positive for tumor).
• Have disease detectable in CNS (confirmed by CT or MRI of the brain at screening or within 8 weeks of randomization).
• Be receiving alternative therapy for the treatment of neuroblastoma, e.g. radiotherapy or chemotherapy within 3 weeks of randomization.
• Require additional therapy (such as radiotherapy) during the first two treatment cycles.
• Have detectable human anti-mouse antibody titers at screening.
• Have received prior anti-GD2 investigational therapies.
• Have a history of allergies to mouse proteins.
• Have an active infection requiring IV infusion of antibiotics.
• Be currently receiving long-term chronic treatment with immunosuppressive drugs such as cyclosporine, adrenocorticotropic hormone (ACTH), or systemic corticosteroids.